Semax, an analog of ACTH<sub>(4-7)</sub>, regulates expression of immune response genes during ischemic brain injury in rats.
Medvedeva. Ekaterina V EV; Dmitrieva. Veronika G VG; Limborska. Svetlana A SA; Myasoedov. Nikolay F NF; Dergunova. Lyudmila V LV
Key Findings
- Semax enhances immune‑response gene expression, especially antigen‑presentation pathways, after ischemic injury
- Semax raises levels of immunoglobulin heavy chain and other cytokine‑related genes in the injured brain
- The PGP fragment alone reduces immune activity and suppresses neurotransmission in the same model
Practical Outcomes
- Semax may offer neuroprotective benefits by modulating brain immune pathways, but the data are from rats and focus on gene activity, not dosage or safety in humans. For self‑experimenters, it highlights a potential mechanism worth watching, yet there’s no clear protocol or dosage recommendation for personal use yet.
Summary
In rats with a brain stroke, the synthetic peptide Semax changed many immune‑related genes, boosting the brain’s ability to present antigens and increasing certain antibody‑related proteins, which may help protect brain cells. The smaller piece of the peptide, PGP, did the opposite, dampening immune activity and reducing brain signaling. These findings suggest Semax’s neuroprotective effect could come from tweaking brain‑immune interactions, but the work is still early and done in animals.
Abstract
Brain stroke continues to claim the lives of million people every year. To build the effective strategies for stroke treatment it is necessary to understand the neuroprotective mechanisms that are able to prevent the ischemic injury. Consisting of the ACTH<sub>(4-7)</sub> fragment and the tripeptide Pro-Gly-Pro (PGP), the synthetic peptide Semax effectively protects brain against ischemic stroke. However, the molecular mechanisms underlying its neuroprotection and participation of PGP in them are still needed to be clarified. To reveal biological processes and signaling pathways, which are affected by Semax and PGP, we performed the transcriptome analysis of cerebral cortex of rats with focal cerebral ischemia treated by these peptides. The genome-wide biochip data analysis detected the differentially expressed genes (DEGs) and bioinformatic web-tool Ingenuity iReport found DEGs associations with several biological processes and signaling pathways. The immune response is the process most markedly affected by the peptide: Semax enhances antigen presentation signaling pathway, intensifies the effect of ischemia on the interferon signaling pathways and affects the processes for synthesizing immunoglobulins. Semax significantly increased expression of the gene encoding the immunoglobulin heavy chain, highly affects on cytokine, stress response and ribosomal protein-encoding genes after occlusion. PGP treatment of rats with ischemia attenuates the immune activity and suppresses neurotransmission in the CNS. We suppose that neuroprotective mechanism of Semax is realized via the neuroimmune crosstalk, and the new properties of PGP were found under ischemia. Our results provided the basis for further proteomic investigations in the field of searching Semax neuroprotection mechanism.
Study Information
pubmed
2017
2017-03-02T00:00:00.000Z
10.1007/s00438-017-1297-1
20
70